Breaking News, Collaborations & Alliances

Takeda, HemoShear Expand NASH Pact

Several drug targets shown to inhibit biological processes associated with inflammation and fibrosis that can lead to nonalcoholic steatohepatitis

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

HemoShear Therapeutics, LLC has extended its partnership with Takeda Pharmaceutical Co. to discover and develop additional novel therapeutics for liver diseases, including nonalcoholic steatohepatitis (NASH). Under the original agreement, HemoShear received upfront payments and R&D funding, and Takeda received exclusive access to HemoShear’s disease modeling platform to discover and develop best-in-class therapeutics for specific liver diseases. HemoShear is eligible to receive mile...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters